MedPath

Sildenafil Impact on Ventricular Function in Patients With Heart Failure

Phase 2
Completed
Conditions
Heart Failure
Interventions
Drug: Placebo
Registration Number
NCT01936350
Lead Sponsor
Hospital Ana Nery
Brief Summary

Twenty-four patients with known heart failure will be recruited. They will undergo a cardiac magnetic resonance for ventricular analyses and after this first exam they will be randomized to placebo or Sildenafil. After one hour drug intake they will undergo another cardiac magnetic resonance to evaluate the drug impact on right and left ventricular function.

Detailed Description

Twenty-four patients with known heart failure will be recruited. They will undergo a cardiac magnetic resonance for ventricular analyses and after this first exam they will be randomized to placebo or sildenafil. After one hour drug intake they will undergo another cardiac magnetic resonance to evaluate the drug impact on right and left ventricular function.

The first and second exams will be performed by the same staff. All patients will be evaluated by two, three and four chambers view. Left and right ventricle quantification analyses will be performed by Argus software.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
24
Inclusion Criteria

Patients with heart failure in stable clinical condition compatible with New York Heart Association functional class I to III. Eligibility criteria is consent to participate in the study after receiving detailed information about procedures, possible clinical benefits, and risks.

Exclusion Criteria

patients with new diagnosed lesions during the procedure, eg pulmonary mass and important claustrophobia, low blood pressure ( systolic blood pressure <90 mmHg or diastolic blood pressure <60 mmHg) nitrate or nebivolol use over the last 48 hours, metallic non MRI compatible implantable devices.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SildenafilSildenafil12 patients will be in this group. They will take a sildenafil 50mg.
PlaceboPlacebo12 patients will be in this group, they will take placebo
Primary Outcome Measures
NameTimeMethod
Improvement on ventricular functionone hour

Patients will undergo a cardiac magnetic resonance to evaluate ventricular function after one hour of sildenafil or placebo use

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hospital Ana Neri - MRI unit

🇧🇷

Salvador, Bahia, Brazil

© Copyright 2025. All Rights Reserved by MedPath